- +1 917 388 8306
- blaine.hackman@dechert.com
- vCard
-
New York OfficeThree Bryant Park, 1095 Avenue of the Americas, New York, NY, United States of America 10036-6797
Blaine M. Hackman, Ph.D. currently focuses his practice on U.S. Patent and Trademark Office post-grant proceedings, patent litigation, and patent counseling, and prosecution. Dr. Hackman has represented pharmaceutical and biotechnology clients in Inter Partes Review (IPR) and Post-Grant Review (PGR) proceedings before the Patent Trial and Appeal Board (PTAB). Dr. Hackman has also represented pharmaceutical and biotechnology clients in intellectual property litigation (including Hatch-Waxman proceedings) and advised on patent issues for numerous transactions. He has also prosecuted patents and counseled clients in transactions in a variety of technologies, including small molecule and protein therapies, nanotechnology, diagnostic imaging, and analytical chemistry.
Dr. Hackman has published, presented, and provided insights on intellectual property-related issues, including publications for Reuters on the legacy of Judge Prost’s opinions and dissents related to life sciences patent law, in Law360 on discretionary denials of PTAB petitions with parallel Hatch-Waxman litigations, and in the annual PTAB Bar Association Law Journal on comparing and contrasting expert discovery protections between the PTAB and district courts. Dr. Hackman has also provided perspectives on patent law in interviews for Bloomberg and Law360. His writing has been recognized by the Licensing Executive Society International Journal, les Nouvelles, for publishing the Article of the Month. He has also been recognized as a Rising Star by Super Lawyers in their intellectual property category in 2017-2023.
- Petitioner, Kymera Therapeutics in a PGR (PGR2021-00115) of USPN 10,849,980, titled “Methods to Induce Targeted Protein Degradation through Bifunctional Molecules.”
- Petitioner BicycleRD in IPR (IPR2020-01569 and IPR2020-01626) of USPNs 8,748,105 and 8,742,070, titled “Method for Selecting a Candidate Drug Compound.”
- Petitioner, Eli Lilly & Co., in a PGR (PGR2019-00043) of USPN 10,011,654, entitled “Antibodies Directed to IL-17A/IL-17F Heterodimers.”
- Pfizer in securing reissue patent RE47,739 in the U.S. Patent and Trademark Office related to its blockbuster cancer treatment, IBRANCE® (palbociclib).
- Royalty Pharma in several transactions, including those relating to Risdiplam, Seltorexant, Vertex’s cystic fibrosis treatments, IDHIFA® (enasidenib), ENTYVIO® (vedolizumab), PREVYMIS™ (letermovir), TAZVERIK® (tazemetostat), and PROMACTA® (eltrombopag).
- A major medical device company as Patent Owner in four IPR proceedings related to patents claiming a minimally invasive continuous glucose monitoring system (CGMS).
- Drugmakers Undercut Rivals With New Patent Tactic as Law Shifts - Bloomberg Law (October 26, 2021)
- Chief Judge Prost: a defender of clarity in patent law - Reuters (June 21, 2021)
- Fintiv Rule Challenges Face Long Odds After Fed. Circ. Ruling - Law360 (March 16, 2021)
- PTAB Sees Fewer Drug Patent Fights as Generics’ Strategy Shifts - Bloomberg Law (February 8, 2021)
-
- Harvey Mudd College, B.S., 2001, High Honors, Dow Chemical Foundation Scholar
- Columbia University, Ph.D., 2006
- Georgetown University Law Center, J.D., 2013
-
- New York
- United States Patent and Trademark Office
- United States Court of Appeals for the Federal Circuit
-
- Patent Trial and Appeal Board (PTAB) Bar Association
- New York Intellectual Property Law Association (NYIPLA)
- American Chemical Society